Liver function and drug processing: a new study

NCT ID NCT07231991

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study looks at how the drug vepdegestrant is processed by the body in people with moderate to severe liver problems compared to healthy people. About 24 adults (ages 18-70) will take a single dose and stay at the clinic for 11 days. The goal is to understand how liver function affects drug levels, which helps guide safe dosing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Pharmacology of Miami
RECRUITING

Miami, Florida, 33172, United States
Floridian Clinical Research, LLC
RECRUITING

Miami Lakes, Florida, 33016, United States
Genesis Clinical Research, LLC
RECRUITING

Tampa, Florida, 33603, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States

Conditions

Explore the condition pages connected to this study.

HEALTHY PARTICIPANTS HEALTHY PARTICIPANTS